Ventus Enters NLRP3 Inhibitor Race With Parkinson’s Candidate
Adds To Novo Nordisk Partnership
Executive Summary
Tricky drug development challenges have held back the NLRP3 inhibitor field for decades but Ventus and its many rivals believe the class can deliver on its huge potential, from Parkinson’s disease to NASH and arthritis.
You may also be interested in...
Roche Bulks Up In NLRP3 With €380m Inflazome Buy
Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.
Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success
The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.
Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?
Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.